The escalating incidence of somatic mutations, which contribute to the progressive overgrowth of fibrous tissue in the liver, disrupting its normal function, is primarily driving the hepatic cirrhosis market. In addition to this, the inflating utilization of effective medications, such as antifibrotic agents, diuretics, and beta-blockers, aimed at managing the condition and averting f... https://www.imarcgroup.com/hepatic-cirrhosis-market